Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors induce myeloma cell apoptosis, suggesting that they could be useful clinically. We conducted a phase II study with the c-MET inhibitor tivantinib in patients with relapsed, or...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Ann Hematol
Κύριοι συγγραφείς: Baljevic, Muhamed, Zaman, Shadia, Baladandayuthapani, Veerabhadran, Lin, Yan Heather, de Partovi, Claudia Morales, Berkova, Zuzana, Amini, Behrang, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Fu, Min, Cleeland, Charles S., Wang, Xin Shelley, Stellrecht, Christine M., Davis, Richard E., Gandhi, Varsha, Orlowski, Robert Z.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer Berlin Heidelberg 2017
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5406425/
https://ncbi.nlm.nih.gov/pubmed/28337527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2980-3
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια